SPEXIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0634 CHF | +0.63% |
|
+16.97% | +54.63% |
| May. 01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 331 365.06 | Sales 2022 | 1.48M 1.63M | Capitalization | 19.96M 22.02M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -12.13M | Net income 2022 | -18M -19.85M | EV / Sales 2021 * | - |
| Net cash position 2021 | 6.23M 6.87M | Net Debt 2022 | 4.23M 4.67M | EV / Sales 2022 | 16.4 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 50.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on Spexis AG
More press releases
| 1 day | +0.63% | ||
| 1 week | +16.97% | ||
| Current month | +7.82% | ||
| 1 month | +6.02% | ||
| 3 months | -70.78% | ||
| 6 months | -2.46% | ||
| Current year | +54.63% |
1 week
0.05
0.06
1 month
0.050.07
Current year
0.041.06
1 year
0.011.06
3 years
0.012.20
5 years
0.012.20
10 years
0.012.20
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.0634 | +0.63% | 75,529 |
| 24-05-08 | 0.063 | -0.94% | 174,707 |
| 24-05-07 | 0.0636 | +4.26% | 296,568 |
| 24-05-06 | 0.061 | +12.55% | 73,300 |
| 24-05-03 | 0.0542 | -15.05% | 182,700 |
Delayed Quote Swiss Exchange, May 10, 2024 at 11:31 am EDT
More quotes
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Sector
Pharmaceuticals
Calendar
2024-09-04
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +54.63% | 4.73M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- POLN Stock